Cited by 170Dementia and Cognitive Impairment ResearchAdvanced Neuroimaging Techniques and ApplicationsAlzheimer's disease research and treatments

White matter integrity and vulnerability to Alzheimer’s disease: preliminary findings and future directions

Open access
Gold, Brian T., Johnson, Nathan F., Powell, David K., Smith, Charles D.·2012·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

Neuroimaging biomarkers that precede cognitive decline have the potential to aid early diagnosis of Alzheimer's disease (AD). A body of diffusion tensor imaging (DTI) work has demonstrated declines in white matter (WM) microstructure in AD and its typical prodromal state, amnestic mild cognitive impairment. The present review summarizes recent evidence suggesting that WM integrity declines are present in individuals at high AD-risk, prior to cognitive decline. The available data suggest that AD-risk is associated with WM integrity declines in a subset of tracts showing decline in symptomatic AD. Specifically, AD-risk has been associated with WM integrity declines in tracts that connect gray matter structures associated with memory function. These tracts include parahippocampal WM, the cingulum, the inferior fronto-occipital fasciculus, and the splenium of the corpus callosum. Preliminary evidence suggests that some AD-risk declines are characterized by increases of radial diffusivity, raising the possibility that a myelin-related pathology may contribute to AD onset. These findings justify future research aimed at a more complete understanding of the neurobiological bases of DTI-based declines in AD. With continued refinement of imaging methods, DTI holds promise as a method to aid identification of presymptomatic AD. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2011.07.009

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AD pathology in the white matter includes loss of myelin and a decrease in oligodendrocyte proteins.

    “AD pathology in the white matter includes the loss of myelin and a decrease in oligodendrocyte proteins [62–68].”

    From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [68]

    The Introduction reports partial loss of myelin sheaths and oligodendroglial cells in AD. The Neurobiological Mechanisms section says myelin proteins are reduced early in the AD process, but does not identify them specifically as oligodendrocyte proteins. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • White matter changes in the preclinical phase before the occurrence of cognitive impairment have been examined only in a few studies.

    “Despite these previous findings in symptomatic Alzheimer’s disease participants, white matter changes in the preclinical phase before the occurrence of cognitive impairment have been examined only in a few studies (Gold et al., 2012).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gold, B. T., Johnson, N. F., Powell, D. K., & Smith, C. D.
Affiliations
University of Kentucky (US)
Corresponding author
Gold, Brian T.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2012-03
Volume
1822
Issue
3
Pages
416-422
ISSN
0925-4439 (ISSN-L)
OpenAlex
W1984939243
Cited by
170
References
68
Citations by year
2026: 10 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 12 · 2021: 6 · 2020: 9 · 2019: 8 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 12 · 2014: 15 · 2013: 16 · 2012: 6
FWCI
1.55
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NINDS (R01 NS-36660)
  • NIA (R01 AG033036)
  • NSF (BCS-0814302)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced Neuroimaging Techniques and Applications
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, white matter integrity, diffusion tensor imaging, amnestic mild cognitive impairment, neuroimaging biomarkers, early diagnosis, radial diffusivity, myelin pathology, cingulum, inferior fronto-occipital fasciculus, splenium of corpus callosum, white matter microstructure
MeSH terms
Alzheimer Disease, Brain, Cognition Disorders, Humans, Nerve Fibers, Myelinated, Risk Factors, Diffusion Tensor Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review